Geriatric Mood Disorders: Page 3 of 3
Geriatric Mood Disorders: Page 3 of 3
In general, the pharmacological treatment of nonpsychotic major depressive disorder in elderly persons is only partially successful: only about half of older adults with depression improve with initial antidepressant monotherapy.55 Many factors may predict a more difficult-to-treat depression, including coexisting anxiety, low self-esteem, poor sleep, and a high coexisting medical burden.56 Being aware of these and other predictors of a difficult-to-treat depression gives the clinician more reasonable expectations about a patient’s likely treatment outcome. Getting well and staying well is the goal of patients; thus, clinicians should treat to remission of depression, not merely to response.56
Maintenance treatment with the same regimen that has been successful in relieving the depression strongly improves the patient’s chances of remaining depression-free. In a recent trial of maintenance treatments, patients 70 years or older with major depression who had responded to initial treatment with paroxetine and psychotherapy were less likely to have recurrent depression if they received 2 years of maintenance therapy with paroxetine.57 Monthly maintenance psychotherapy did not prevent recurrent depression. This is unexpected given earlier reports of improved response to the combined treatments, and thus, needs to be replicated.
Randomized trials have compared different strategies for management of nonmajor depression, mostly in primary care settings. In a recent meta-analysis, Pinquart and colleagues58 integrated the results of 89 controlled studies of treatments for acute major depression (37 studies) and other depressive disorders (52 studies conducted with mixed diagnostic groups, including patients with major depression, minor depression, and dysthymia). Psychosocial treatments had larger effect sizes for less severe forms of depression than pharmacological treatments.
Two collaborative trials have addressed the efficacy of antidepressant treatment in patients with depressive syndromes treated in primary care settings. The Prevention of Suicide in the Primary Care Elderly Collaborative Trial (PROSPECT) study, which was supported by the NIMH, and theImproving Mood: Promoting Access to Collaborative Treatment for Late Life Depression (IMPACT) study, which was supported by the Hartford Foundation, evaluated the effectiveness of current models by nurse health specialists.59,60 Results showed that the PROSPECT intervention substantially reduced suicidal ideation at rates comparable to those seen in earlier efficacy studies and in specialty mental health clinical settings.61 The IMPACT intervention was effective in improving symptomatic and functional outcomes for older primary care patients with major depression or dysthymic disorder.60 The studies on collaborative treatments are important and the components of collaborative care can be transported into clinical practice emphasizing early diagnosis and treatment of depression in primary care settings.
Esther, a 72-year-old, presents with complaints of insomnia, weight loss, and sadness over the loss of her husband 2 years ago. She is socially isolated, lives alone, and rarely leaves her house. Esther is able to cook simple meals. She still drives short distances, but on several occasions she has forgotten her appointments.
Her medical problems include hypertension, coronary artery disease, hyperlipidemia, and stress incontinence. When her primary care physician prescribed 10 mg of nortriptyline at night to treat the depression, incontinence, insomnia, and poor appetite, she became agitated, confused, and disoriented. She was taken to the emergency department where delirium was diagnosed. The patient was admitted to the geriatric psychiatry unit.
A CT scan of her head showed some age-related generalized atrophy and old microvascular disease in the deep white matter and periventricular but no acute stroke. The ECG showed QTC-interval prolongation but no acute ischemic changes.
Esther was given 0.5 mg of haloperidol for agitation and belligerence, and nortriptyline was discontinued. Over the next 5 days, her confusion and agitation subsided, but she showed mild extrapyramidal signs caused by the haloperidol, which was discontinued by day 5.
Neuropsychological testing revealed deficits in executive functioning and psychomotor slowing; however, dementia was ruled out. Esther was given 15 mg of mirtazapine at night: she became more animated, less withdrawn, participated in group activities, and enjoyed the company of other patients. Her appetite and sleep improved as well. There were no changes from baseline on subsequent ECGs, and Esther was discharged with recommendations for admission to a day treatment program and individual psychotherapy or grief counseling with structured activities to increase social stimulation, as well as recommendations for local resources and support groups.
The antidepressant selection that was ultimately successful for Esther considered her vulnerability to anticholinergics and the central and cardiac adverse effects of nortriptyline that led to the patient’s confusion and hospitalization. The selection of mirtazapine addressed her symptoms of depression, as well as incontinence, insomnia, and poor appetite without exposing Esther to the detrimental anticholinergic adverse effects.
Despite recent advances in our understanding of pathophysiology of geriatric depression and the development of treatment approaches similar to that in younger adults, the available treatments are only modestly effective. Our current understanding of the pathophysiology of geriatric depression complicated by medical, vascular, and neurodegenerative processes should lead to the development of more personalized treatment approaches based on individual risk factors. For example, treatment of depression should be different for those who are depressed due to complicated bereavement than for those who become depressed at the beginning of Alzheimer disease. So far, recommended treatments have not differed and have followed the drug development paradigm for younger adults: no consideration has been given to differences in pathophysiology in aging adults, which poses challenges to future research.
General considerations when choosing a drug regimen for older adults should include age-related changes in pharmacokinetics and pharmacodynamics of the drugs and in the structure and function of the brain and other organs that lead older adults to be more sensitive to both therapeutic and toxic effects of psychotropic medications. Such changes necessitate lower doses and slower dose titration. Although the effective dose may be similar to that for younger adults, the initial dose of psychotropic medications for older adults should be one-third to one-half of that for younger adults and titrated slowly. The groups that may be particularly vulnerable to the adverse effects and drug-drug interactions include frail older adults with multiple medical problems or those with cognitive impairment, dementia, or other neurodegenerative disorders or who have had a stroke. Lower doses of drugs and augmentation strategies with other drugs and supplements should be considered (eg, cognitive enhancers and neuroprotective agents in patients with cognitive impairment; or psychostimulants or dopaminergic agents in patients with apathy or Parkinson disease). Table 2 (Table restricted. Please see print version for content.) lists the recommended dosages of antidepressants for older adults.
1. Reynolds CF 3rd, Dew MA, Lenze EJ, Whyte EM. Preventing depression in medical illness: a new lead? Arch Gen Psychiatry. 2007;64:884-885.
2. Weyerer S, Eifflaender-Gorfer S, Kšhler L, et al. Prevalence and risk factors for depression in non-demented primary care attenders aged 75 years and older. J Affect Disord. 2008 Mar 25 [Epub ahead of print].
3. Charney DS, Reynolds CF 3rd, Lewis L, et al. Depression and Bipolar Support Alliance consensus statement on the unmet needs in diagnosis and treatment of mood disorders in late life. Arch Gen Psychiatry. 2003;60:664-672.
4. Flint AJ. The complexity and challenge of non-major depression in late life. Am J Geriatr Psychiatry. 2002;10:229-232.
5. Lyness JM, Kim J, Tang W, et al. The clinical significance of subsyndromal depression in older primary care patients. Am J Geriatr Psychiatry. 2007;51:1554-1562.
6. Rosen J, Mulsant GH, Pollock BG. Sertraline in the treatment of minor depression in nursing home residents: a pilot study. Int J Geriatr Psychiatry. 2000;15: 177-180.
7. Beekman AT, Deeg DJ, Braam AW, et al. Consequences of major and minor depression in later life: a study of disability, well-being and service utilization. Psychol Med. 1997;27:1397-1409.
8. Lavretsky H, Kumar A. Clinically significant non-major depression: old concepts, new insights. Am J Geriatr Psychiatry. 2002;10:239-255.
9. Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry. 1998;55:694-700.
10. Aziz R, Lorberg B, Tampi RR. Treatments for late life bipolar disorder. Am J Geriatr Pharmacother. 2006;4:347-64.
11. Sajatovic M, Madhusoodanan S, Coconcea N. Managing bipolar disorder in the elderly: defining the role of the newer agents. Drugs Aging. 2005;22:39-54.
12. Subramaniam H, Dennis MS, Byrne EJ. The role of vascular risk factors in late onset bipolar disorder. Int J Geriatr Psychiatry. 2007;22:733-737.
13. Young RC, Gyulai L, Mulsant BH, et al. Pharmacotherapy of bipolar disorder in old age: review and recommendations. Am J Geriatr Psychiatry. 2004;12: 342-357.
14. Sajatovic M, Coconcea N, Ignacio RV, et al. Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. J Clin Psychiatry. 2008;69:41-46.
15. Andreescu C, Mulsant BH, Peasley-Miklus C, et al. Persisting low use of antipsychotics in the treatment of major depressive disorder with psychotic features. J Clin Psychiatry. 2007;68:194-200.
16. Rothschild AJ, Winer J, Flint AJ, et al. Missed diagnosis of psychotic depression at 4 academic medical centers. J Clin Psychiatry. 2008 Apr 1:e1-e4 [Epub ahead of print].
17. Andreescu C, Lenze EJ, Dew MA, et al. Effect of comorbid anxiety on treatment response and relapse risk in late-life depression: controlled study. Br J Psychiatry. 2007;190:344-349.
18. Alexopoulos GS, Meyers BS, Young RC, et al. “Vascular depression” hypothesis. Arch Gen Psychiatry. 1997;54:915-922.
19. Krishnan KR, Hays JC, Blazer DG. MRI-defined vascular depression. Am J Psychiatry. 1997;154:497-501.
20. Taylor WD, Steffens DC, Krishnan KR. Psychiatric disease in the twenty-first century: the case for subcortical ischemic depression. Biol Psychiatry. 2006; 60:1299-1303.
21. Fujikawa T, Yokota N, Muraokaet M, et al. Response of patients with major depression and silent cerebral infarction to antidepressant drug therapy, with emphasis on central nervous system adverse reactions. Stroke. 1996;27:2040-2042.
22. Kumar A, Mintz J, Bilker W, et al. Autonomous neurobiological pathways to late-life major depressive disorder: clinical and pathophysiological implications. Neuropsychopharmacology. 2002;26:229-236.
23. O’Brien JT, Firbank MJ, Krishnan MS, et al. White matter hyperintensities rather than lacunar infarcts are associated with depressive symptoms in older people: the LADIS study. Am J Geriatr Psychiatry. 2006;14:834-841.
24. Taylor WD, Bae JN, MacFall JR, et al. Widespread effects of hyperintense lesions on cerebral white matter structure. AJR. 2007;188:1695-1704.
25. Jagust WJ, Zheng L, Harvey DJ, et al. Neuropathological basis of magnetic resonance images in aging and dementia. Ann Neurol. 2008;63:72-80.
26. Jorge RE, Moser DJ, Acion L, Robinson RG. Treatment of vascular depression using repetitive transcranial magnetic stimulation. Arch Gen Psychiatry. 2008;65:268-276.
27. Unutzer J, Patrick DL, Simon G, et al. Depressive symptoms and the cost of health services in HMO patients aged 65 years and older: a 4-year prospective study. JAMA. 1997;277:1618-1623.
28. Barrett JE, Williams JW, Oxman TE, et al. The treatment effectiveness project. A comparison of the effectiveness of paroxetine, problem-solving therapy, and placebo in the treatment of minor depression and dysthymia in primary care patients: background and research plan. Gen Hosp Psychiatry. 1999;21:260-273.
29. Zisook S, Paulus M, Shuchter SR, et al. The many faces of depression following spousal bereavement. J Affect Disor. 1997; 45:85-94.
30. Devanand DP. Comorbid psychiatric disorders in late life depression. Biol Psychiatry. 2002;52:236-242.
31. Butters MA, Bhalla RK, Mulsant BH, et al. Executive functioning, illness course, and relapse/recurrence in continuation and maintenance treatment of late-life depression: is there a relationship? Am J Geriatr Psychiatry. 2004;12:387-394.
32. Nebes RD, Butters MA, Mulsant BH, et al. Decreased working memory and processing speed mediate cognitive impairment in geriatric depression. Psychol Med. 2000;30:679-691.
33. Alexopoulos GS, Meyers BS, Young RC, et al. Executive dysfunction and long-term outcomes of geriatric depression. Arch Gen Psychiatry. 2000;57:285-290.
34. Elderkin-Thompson V, Mintz J, Haroon E, et al. Executive dysfunction and memory in older patients with major and minor depression. Arch Clin Neuropsychol. 2006;21:669-676.
35. Devanand DP, Sano M, Tang MX, et al. Depressed mood and the incidence of Alzheimer’s disease in the elderly living in the community. Arch Gen Psychiatry. 1996;53:175-182.
36. Jorm AF. History of depression as a risk factor for dementia: an updated review. Aust N Z J Psychiatry. 2001;35:776-781.
37. Lavretsky H, Ercoli L, Siddarth P, et al. Apolipoprotein epsilon4 allele status, depressive symptoms, and cognitive decline in middle-aged and elderly persons without dementia. Am J Geriatr Psychiatry. 2003;11: 667-673.
38. Beekman AT, de Beurs E, van Balkom AJ, et al. Anxiety and depression in later life: co-occurrence and communality of risk factors. Am J Psychiatry. 2000;157:89-95.
39. Smith GS, Gunning-Dixon FM, Lotrich FE, et al. Translational research in late-life mood disorders: implications for future intervention and prevention research. Neuropsychopharmacology. 2007;32:1857-1875.
40. Steffens DC, Potter GG, McQuoid DR, et al. Longitudinal magnetic resonance imaging vascular changes, apolipoprotein E genotype, and development of dementia in the neurocognitive outcomes of depression in the elderly study. Am J Geriatr Psychiatry. 2007;15:839-849.
41. Whyte EM, Pollock BG, Wagner WR, et al. Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geriatric depression. Am J Psychiatry. 2001;158:2074-2076.
42. Lavretsky H, Siddarth P, Kumar A, Reynolds CF 3rd.The effects of the dopamine and serotonin transporter polymorphisms on clinical features and treatment response in geriatric depression: a pilot study. Int J Geriatr Psychiatry. 2008;23:55-59.
43. Lenze EJ, Shardell M, Ferrell RE, et al. Association of serotonin-1A and 2A receptor promoter polymorphisms with depressive symptoms and functional recovery in elderly persons after hip fracture. J Affect Disord. In press.
44. Lotrich FE, Pollock BG, Kirshner M, et al. Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci. 2008;33: 123-130.
45. Teodorczuk A, O’Brien JT, Firbank MJ, et al. White matter changes and late-life depressive symptoms: longitudinal study. Br J Psychiatry. 2007;191:212-217.
46. Sheline YI, Price JL, Vaishnavi SN, et al. Regional white matter hyperintensity burden in automated segmentation distinguishes late-life depressed subjects from comparison subjects matched for vascular risk factors. Am J Psychiatry. 2008;165:524-532.
47. Yuan Y, Zhang Z, Bai F, et al. White matter integrity of the whole brain is disrupted in first-episode remitted geriatric depression. Neuroreport. 2007;18: 1845-1849.
48. Alexopoulos GS, Murphy CF, Gunning-Dixon FM, et al. Microstructural white matter abnormalities and remission of geriatric depression. Am J Psychiatry. 2008;165:238-244.
49. Lavretsky H, Ballmaier M, Pham D, et al. Neuroanatomical characteristics of geriatric apathy and depression: a magnetic resonance imaging study. Am J Geriatr Psychiatry. 2007;15:386-394.
50. Lavretsky H, Zheng L, Mack W, et al. The neuroanatomical MRI patterns associated with neuropsychiatric symptoms in older adults with and without cognitive impairment. Int J Geriatr Psychiatry. In press.
51. Kumar A, Jin Z, Bilker W. Late-onset and major depression: early evidence for common neuroanatomical substrates detected by using MRI. ProcNatl Sci. 1998;95:7654-7658.
52. Sheline YI, Mintun MA, Barch DM, et al. Decreased hippocampal 5-HT(2A) receptor binding in older depressed patients using[18F]altanserin positron emission tomography. Neuropsychopharmacology. 2004; 29:2235-2241.
53. Meltzer CC, Price JC, Mathis CA, et al. Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology. 2004;29: 2258-2265.
54. Sweet RA, Hamilton RL, Butters MA, et al. Neuropathologic correlates of late-onset major depression. Neuropsychopharmacology. 2004;29:2242-2250.
55. Alexopoulos GS, Katz IR, Reynolds CF 3rd, et al. Pharmacotherapy of depressive disorders in older patients. Postgrad Med. 2001;Spec No Pharmacotherapy:1-86.
56. Driscoll HC, Karp JF, Dew MA, Reynolds CF 3rd. Getting better, getting well: understanding and managing partial and non-response to pharmacological treatment of non-psychotic major depression in old age. Drugs Aging. 2007;24:801-814.
57. Reynolds CF 3rd, Dew MA, Pollock BG, et al. Maintenance treatment of major depression in old age. N Engl J Med. 2006;354:1130-1138.
58. Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy. Am J Psychiatry. 2006;163:1493-1501.
59. Bruce ML, Pearson JL. Designing an intervention to prevent suicide: PROSPECT (Prevention of Suicide in Primary Care Elderly Collaborative Trial). Dialogues Clin Neurosci. 1999;1:100-112.
60. Katz IR, Coyne JC. The public health model for mental health care for the elderly. JAMA. 2000;283:1-6.
61. Bruce ML, Ten Have TR, Reynolds CF III, et al. Reducing suicidal ideation and depressive symptoms in depressed older primary care patients: a randomized controlled trial. JAMA.2004;291:1081-1091.
62. Lavretsky H, Kumar A. Practical geriatrics: clinically significant nonmajor geriatric depression. Psychiatr Serv. 2003;54:297-299.
63. Lavretsky H. Treatment of behavioral disturbances in patients with dementia: research applications: translating evidence into practice. CME Supplement to Psychiatric Times. December 2004:1-8.